OBJECTIVE: Natural killer T (NKT) cells are efficiently targeted by HIV and severely reduced in numbers in the circulation of infected individuals. The functional capacity of the remaining NKT cells in HIV-infected individuals is poorly characterized. This study measured NKT cell cytokine production directly ex vivo and compared these responses with both the disease status and NKT subset distribution of individual patients. METHODS: NKT cell frequencies, subsets, and ex-vivo effector functions were measured in the peripheral blood mononuclear cells of HIV-infected patients and healthy controls by flow cytometry. We measured cytokines from NKT cells after stimulation with either alpha-galactosyl ceramide-loaded CD1d dimers (DimerX-alphaGalCer) or phorbol myristate acetate and ionomycin. RESULTS: The frequencies of NKT cells secreting interferon-gamma and tumor necrosis factor-alpha were significantly lower in HIV-infected patients than healthy controls after DimerX-alphaGalCer treatment, but responses were similar after treatment with phorbol myristate acetate and ionomycin. The magnitude of the interferon-gamma response to DimerX-alphaGalCer correlated inversely with the number of years of infection. Both interferon-gamma and tumor necrosis factor-alpha production in response to DimerX-alphaGalCer correlated inversely with CD161 expression. CONCLUSION: The ex-vivo Th1 responses of circulating NKT cells to CD1d-glycolipid complexes are impaired in HIV-infected patients. NKT cell functions may be progressively lost over time in HIV infection, and CD161 is implicated in the regulation of NKT cell responsiveness.
OBJECTIVE: Natural killer T (NKT) cells are efficiently targeted by HIV and severely reduced in numbers in the circulation of infected individuals. The functional capacity of the remaining NKT cells in HIV-infected individuals is poorly characterized. This study measured NKT cell cytokine production directly ex vivo and compared these responses with both the disease status and NKT subset distribution of individual patients. METHODS: NKT cell frequencies, subsets, and ex-vivo effector functions were measured in the peripheral blood mononuclear cells of HIV-infectedpatients and healthy controls by flow cytometry. We measured cytokines from NKT cells after stimulation with either alpha-galactosyl ceramide-loaded CD1d dimers (DimerX-alphaGalCer) or phorbol myristate acetate and ionomycin. RESULTS: The frequencies of NKT cells secreting interferon-gamma and tumor necrosis factor-alpha were significantly lower in HIV-infectedpatients than healthy controls after DimerX-alphaGalCer treatment, but responses were similar after treatment with phorbol myristate acetate and ionomycin. The magnitude of the interferon-gamma response to DimerX-alphaGalCer correlated inversely with the number of years of infection. Both interferon-gamma and tumor necrosis factor-alpha production in response to DimerX-alphaGalCer correlated inversely with CD161 expression. CONCLUSION: The ex-vivo Th1 responses of circulating NKT cells to CD1d-glycolipid complexes are impaired in HIV-infectedpatients. NKT cell functions may be progressively lost over time in HIV infection, and CD161 is implicated in the regulation of NKT cell responsiveness.
Authors: Karina I Carvalho; Fernanda R Bruno; Jennifer E Snyder-Cappione; Solange M Maeda; Jane Tomimori; Marilia B Xavier; Patrick A Haslett; Douglas F Nixon; Esper G Kallas Journal: Immunology Date: 2012-05 Impact factor: 7.397
Authors: Dominic Paquin-Proulx; Anna Gibbs; Susanna M Bächle; Antonio Checa; Andrea Introini; Edwin Leeansyah; Craig E Wheelock; Douglas F Nixon; Kristina Broliden; Annelie Tjernlund; Markus Moll; Johan K Sandberg Journal: J Immunol Date: 2016-08-01 Impact factor: 5.422
Authors: C Kuylenstierna; J E Snyder-Cappione; C P Loo; B R Long; V D Gonzalez; J Michaëlsson; M Moll; G Spotts; F M Hecht; D F Nixon; J K Sandberg Journal: Scand J Immunol Date: 2011-02 Impact factor: 3.487
Authors: Marianne W Mureithi; Kristen Cohen; Ramona Moodley; Danielle Poole; Zenele Mncube; Anne Kasmar; D Branch Moody; Philip J R Goulder; Bruce D Walker; Marcus Altfeld; Thumbi Ndung'u Journal: AIDS Res Hum Retroviruses Date: 2010-12-13 Impact factor: 2.205
Authors: L C Ndhlovu; J E Snyder-Cappione; K I Carvalho; F E Leal; C P Loo; F R Bruno; A R Jha; D Devita; A M Hasenkrug; H M R Barbosa; A C Segurado; D F Nixon; E L Murphy; E G Kallas Journal: Clin Exp Immunol Date: 2009-09-02 Impact factor: 4.330
Authors: Jennifer E Snyder-Cappione; Camilla Tincati; Ijeoma G Eccles-James; Amedeo J Cappione; Lishomwa C Ndhlovu; Laura L Koth; Douglas F Nixon Journal: PLoS One Date: 2010-11-03 Impact factor: 3.240
Authors: Britta Flach; Prossy Naluyima; Kim Blom; Veronica D Gonzalez; Leigh Anne Eller; Oliver Laeyendecker; Thomas C Quinn; David Serwadda; Nelson K Sewankambo; Maria J Wawer; Ronald H Gray; Nelson L Michael; Fred Wabwire-Mangen; Merlin L Robb; Michael A Eller; Johan K Sandberg Journal: J Acquir Immune Defic Syndr Date: 2013-07-01 Impact factor: 3.731
Authors: Jennifer E Snyder-Cappione; Douglas F Nixon; Joyce C Chi; Michelle-Linh T Nguyen; Christopher K Kirby; Jeffrey M Milush; Laura L Koth Journal: Eur J Immunol Date: 2013-06-25 Impact factor: 5.532